Opinion|Videos|May 13, 2024
Evolving Perception of Autonomous Adrenal Hypercortisolism
Ralph DeFronzo, MD, leads a discussion on the evolving perception of autonomous adrenal hypercortisolism, highlighting that its prevelance is significantly greater than previously understood.
Advertisement
Episodes in this series
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
Advances in Treating High-Impact Psoriasis from EADV 2026
3
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
4
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines to Include HYPERION Data
5